Taipei, Taiwan

The National Taiwan University Hospital started operations under Japanese rule in Daitōtei on June 18, 1895, and moved to its present location in 1898. The Hospital was later annexed to the Medical School of Taihoku Imperial University and renamed Taihoku Imperial University Medical School Affiliated Hospital in 1937. The present name was adopted after the Republic of China took over the hospital upon Taiwan's retrocession in 1945.On October 19, 1991, the completion of a large new building complex on the so-called East Site marked another milestone in the history of the NTUH. Today, the East and West Sites together have more than 4,000 employees, serving 2,000 inpatients and 8,000 outpatients daily. The hospital remains the best-known and most highly renowned medical center in Taiwan.The hospital is a world-renowned medical center for liver diseases. Advanced surgical, angiographical, and endoscopic procedures are routinely performed. Wikipedia.


Time filter

Source Type

Patent
National Tsing Hua University, National Taiwan University Hospital and National Taiwan University | Date: 2015-12-03

An image analysis method and an apparatus thereof for assessment of PD (peritoneal dialysis) complications in peritoneal dialysis are provided. An analysis procedure is executed on an image under test of a dialysis bag, so as to obtain a color location in a color space corresponding to the image under test. A prompt signal is sent when the color locations obtained in a time period gradually become close to a disease warning range after executing the analysis procedure on a plurality of images under test.


Kao J.-H.,National Taiwan University Hospital
Liver International | Year: 2014

Although chronic hepatitis B (CHB) is a global health threat, it is now a preventable and treatable disease. Seven agents have been approved for the treatment of CHB. Although many patients prefer potent long-term nucleos(t)ide analogues (NAs) as the first-line therapy because they are convenient to use and well-tolerated, a finite duration of pegylated interferon (PEG-IFN) is still an attractive strategy because it provides higher rates of off-therapy host immune control over hepatitis B virus (HBV) compared with NAs. In addition, the rates of HBeAg/HBsAg loss or seroconversion increase over time in patients who respond to PEG-IFN therapy. Nevertheless, these benefits are limited to 30% of all patients, and significant adverse effects are still a concern. Therefore, patients who can benefit most from PEG-IFN therapy should be more carefully selected according to baseline host and viral predictors, such as age, ALT level, viral load, HBV genotype and HBV mutants. In addition, on-treatment predictors including HBV DNA, HBeAg and HBsAg kinetics, can help decide who should continue or discontinue PEG-IFN and shift to NA. Understanding these factors can help determine personalized PEG-IFN therapy for CHB patients. In the near future, the treatment paradigm of CHB should be tailored on the basis of viral (HBV DNA level, HBV genotype and HBV mutants) and host (age, gender, ALT level and host genetic polymorphisms) factors, disease status (stage of fibrosis and comorbidities) and the selection of antiviral agents (immunomodulatory effect, antiviral potency, adverse effects and rate of drug resistance). © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


Cheng A.L.,National Taiwan University Hospital
Journal of clinical oncology : official journal of the American Society of Clinical Oncology | Year: 2013

Open-label, phase III trial evaluating whether sunitinib was superior or equivalent to sorafenib in hepatocellular cancer. Patients were stratified and randomly assigned to receive sunitinib 37.5 mg once per day or sorafenib 400 mg twice per day. Primary end point was overall survival (OS). Early trial termination occurred for futility and safety reasons. A total of 1,074 patients were randomly assigned to the study (sunitinib arm, n = 530; sorafenib arm, n = 544). For sunitinib and sorafenib, respectively, median OS was 7.9 versus 10.2 months (hazard ratio [HR], 1.30; one-sided P = .9990; two-sided P = .0014); median progression-free survival (PFS; 3.6 v 3.0 months; HR, 1.13; one-sided P = .8785; two-sided P = .2286) and time to progression (TTP; 4.1 v 3.8 months; HR, 1.13; one-sided P = .8312; two-sided P = .3082) were comparable. Median OS was similar among Asian (7.7 v 8.8 months; HR, 1.21; one-sided P = .9829) and hepatitis B-infected patients (7.6 v 8.0 months; HR, 1.10; one-sided P = .8286), but was shorter with sunitinib in hepatitis C-infected patients (9.2 v 17.6 months; HR, 1.52; one-sided P = .9835). Sunitinib was associated with more frequent and severe adverse events (AEs) than sorafenib. Common grade 3/4 AEs were thrombocytopenia (29.7%) and neutropenia (25.7%) for sunitinib; hand-foot syndrome (21.2%) for sorafenib. Discontinuations owing to AEs were similar (sunitinib, 13.3%; sorafenib, 12.7%). OS with sunitinib was not superior or equivalent but was significantly inferior to sorafenib. OS was comparable in Asian and hepatitis B-infected patients. OS was superior in hepatitis C-infected patients who received sorafenib. Sunitinib-treated patients reported more frequent and severe toxicity.


Chen D.-S.,National Taiwan University Hospital
Hepatology | Year: 2011

Viral hepatitis and its sequelae are important health problems worldwide, including Taiwan. For the last 40 years, Taiwan's scientists and health care providers have worked hard to control these sequelae, and the results have been excellent. The author, Ding-Shinn Chen, had a key role in planning and establishing the control program in Taiwan, and participated in the endeavors from the very beginning. In this perspective, he describes how he became interested in research as a medical student, his encounters with hepatitis B and C, how he and his colleagues started early detection of hepatocellular carcinoma (HCC), how he helped Taiwan's government create and implement the Viral Hepatitis Control Program, and how the effectiveness of the program in the decrease of hepatitis B carriage and HCC was monitored. He also discusses how he pioneered the use of interferon-α plus ribavirin to treat chronic hepatitis C. Hepatitis B viral load as a risk factor for HCC and cirrhosis in hepatitis B surface antigen carriers is reviewed briefly, as is the prevention of sequelae by antiviral therapies. Finally, Dr. Chen discusses unresolved issues that must be addressed and predicts the changes of the patterns of liver disease in Taiwan beyond the mid-21st century, which is in part affected by the fight against viral hepatitis that was initiated in the early 1980s. Conclusion: Dr. Chen's perspective illustrates Taiwan's fight against viral hepatitis over the last 40 years. This experience can be shared by other countries in which the disease is equally prevalent. © 2011 American Association for the Study of Liver Diseases.


Aim: To test the technical feasibility of laparoscopic lateral pelvic lymph node dissection for patients with clinically positive lateral node(s) after preoperative concurrent chemoradiation therapy for lower rectal cancer. Methods: The operation procedures are detailed in the attached video. Results: Forty-five procedures of laparoscopic lateral pelvic lymphadenectomy were performed in 34 patients, with dissection over bilateral lateral node foci in 11 patients and dissection over unilateral lateral node station in 23. There were four procedures in which the metastatic node was very close to or even encased the adjacent iliac vessel and therefore the lymphadenectomy was done with a surgical margin of less than 1 mm. The median (range) number of lymph nodes harvested in each lateral station was 6 (2-14). Lympho-adipose tissues from 32 (71.1%, 32/45) lateral node dissections were confirmed by histopathology to harbor metastatic adenocarcinoma. For unilateral lateral pelvic lymph node dissection, median (range) blood loss was 44 (20-240) ml and median (range) operation time was 58 (42-94) min. There was one (2.9%) operative mortality and seven (20.6%) postoperative complications. Postoperatively, most patients presented with mild postoperative pain and quick convalescence. During follow-up (mean 24 months), nine patients (27.3%) developed recurrent disease. Remarkably, all four patients with surgical margin less than 1 mm developed cancer recurrence. Conclusions: Laparoscopic lateral pelvic lymphadenectomy is technically feasible for some selected patients. To date, laparoscopic approach is still underdeveloped to treat the complex clinical condition in which the metastatic node involves the iliac vessel and combined resection of the vessel is required to obtain sufficient margin. © 2010 Society of Surgical Oncology.


Tseng C.-H.,National Taiwan University Hospital
Diabetologia | Year: 2011

Aims/hypothesis: Studies on the link between diabetes and bladder cancer in Asians are rare. We investigated the association between diabetes and incidence of bladder cancer by using a large national insurance database. Methods: A random sample of 1,000,000 individuals covered by the National Health Insurance was recruited. A total of 495,199 men and 503,748 women for all ages and 187,609 men and 189,762 women ≥40 years old and without bladder cancer at recruitment were followed from 2003 to 2005. Cox regression evaluated the adjusted relative risk for all ages and for age ≥40 years old. Results: The results were similar for all ages and for age ≥40 years. In Cox models, patients with diabetes consistently showed a significantly higher relative risk ranging from 1.36 to 1.51 after adjustment for age, sex and other potential confounders. Age, male sex, nephropathy, urinary tract diseases (infection and stone) and statin use were associated with bladder cancer, but occupation, hypertension, stroke, ischaemic heart disease, peripheral arterial disease, eye disease, dyslipidaemia and medications (oral glucose-lowering agents including sulfonylurea, metformin, acarbose and thiazolidinediones, insulin, fibrates, ACE inhibitors/angiotensin receptor blockers and calcium channel blockers) were not. Chronic obstructive pulmonary disease and living in regions other than Metropolitan Taipei were associated with lower risk. Conclusions: Patients with diabetes have a higher risk of bladder cancer. The association with urinary tract diseases suggests a complex scenario in the link between bladder cancer and diabetes at different disease stages. © 2011 Springer-Verlag.


Alterations of galectin-3 expression are often seen in cancers and may contribute to tumorigenesis, cancer progression, and metastasis. The studies concerning clinical implications of galectin-3 expression in patients with acute myeloid leukemia (AML) are scarce. We investigated the expression of LGALS3, the gene encoding galectin-3, in the bone marrow (BM) mononuclear cells from an original cohort comprising 280 adults with primary non-acute promyelocytic leukemia. Higher LGALS3 expression was closely associated with older age, French-American-British M4/M5 subtypes, CD14 expression on leukemic cells, and PTPN11 mutation, but negatively correlated with CEBPA mutation and FLT3-ITD. Compared with patients with lower LGALS3 expression, those with higher expression had lower complete remission rates, higher primary refractory rates, and shorter overall survival. This result was validated in an independent validation cohort. A scoring system incorporating higher LGALS3 expression and 8 other risk factors, including age, white blood cell count, cytogenetics, and gene mutations, into survival analysis proved to be very useful to stratify patients with AML into different prognostic groups (P < .001). In conclusion, BM LGALS3 expression may serve as a new biomarker to predict clinical outcome in patients with AML, and galectin-3 may serve as a potential therapeutic target in those patients with higher expression of this protein.


Patent
National Taiwan University Hospital | Date: 2016-07-22

Provided is a device of automatic mechanical wound opener for head and neck surgery. The device includes a wound opener including: a fixed unit and a plurality of drawing units, and at least one of the drawing units being movably connected on the fixed unit, wherein each of the drawing units includes a first arm, a second arm, and a blade connected to the second arm; wherein the first arm is connected to the fixed unit by one end thereof and to the second arm by the other end thereof; the second arm can be adjusted to an needed included angle relative to the first arm; and at least one of the blades includes an extension plate connected to an end of a plate part of the blade, and the extension plate is connected to the second arm for shortening the spacing between two blades.


Patent
National Chiao Tung University and National Taiwan University Hospital | Date: 2015-04-14

A method for measuring two pupils includes a number of steps. A first visible light beam and a first invisible light beam are emitted toward a right eye. A second visible light beam and a second invisible light beam are emitted toward a left eye. The light beams reflected from the right eye and the left eye are received by an optical unit, and the first invisible light beam and the second invisible light beam are guided to an imaging unit by the optical unit. Images of the right eye and the left eye are respectively recorded through the first invisible light and the second invisible light beam propagated from the optical unit.


Patent
National Taiwan University Hospital | Date: 2015-12-03

A drug carrier and a manufacturing method thereof are provided. The drug carrier includes a hydrophilic group, a hydrophobic group and an organic dye. The hydrophilic group and the hydrophobic group are connected by the organic dye. A plurality of the drug carriers are self-assemblable in a polar solvent to form a nanomicelle. The hydrophilic groups are located at the outer region of the nanomicelle, and the hydrophobic groups are located at the inner region of the nanomicelle.

Loading National Taiwan University Hospital collaborators
Loading National Taiwan University Hospital collaborators